Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved the allotment of 24,10,431 equity shares with a face value of Rs 10 each, issued at Rs 115 per share, including a premium of Rs 105. The company's paid-up equity share capital now stands at Rs 10,92,27,910, comprising 1,09,22,791 equity shares. The allotment was made to 15 investors, including Vijay Rathee, Vijaylaxmi Infra Projects Private Limited, and Swapneel Pradeep Rane, with Vijay Rathee receiving 13,17,391 shares.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved the allotment of 24,10,431 equity shares with a face value of Rs 10 each, issued at Rs 115 per share, including a premium of Rs 105. The company's paid-up equity share capital now stands at Rs 10,92,27,910, comprising 1,09,22,791 equity shares. The allotment was made to 15 investors, including Vijay Rathee, Vijaylaxmi Infra Projects Private Limited, and Swapneel Pradeep Rane, with Vijay Rathee receiving 13,17,391 shares.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors, both effective September 4, 2026, following a board meeting. The board also recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director and approved proposed increases in remuneration for Mr. Sakalkar, Mrs. Saili Jayaram More (Whole-time Director and CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), all subject to member approval.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors, both effective September 4, 2026, subject to shareholder approval. The board also recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director and approved increases in remuneration for Mr. Sakalkar, Mrs. Saili Jayaram More (Whole-time Director and CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), pending member approval.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors, both effective September 4, 2026, following a board meeting. The board also recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director and approved proposed increases in remuneration for Mr. Sakalkar, Mrs. Saili Jayaram More (Whole-time Director and CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), all subject to member approval.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, announced that its board of directors approved the appointment of M/s Yash A. Jain & Associates as Internal Auditor and M/s Panchal S K & Associates as Statutory Auditors, both effective September 4, 2026, subject to shareholder approval. The board also recommended the re-appointment of Mr. Ashish Narayan Sakalkar as Managing Director and approved increases in remuneration for Mr. Sakalkar, Mrs. Saili Jayaram More (Whole-time Director and CEO), and Mr. Sachin Chandrakant Badakh (Non-Executive Director), pending member approval.

Asston Pharmaceuticals Limited will hold a board meeting on September 4, 2026, to approve the appointment of M/s Panchal S K & Associates as Statutory Auditor, consider directors retiring by rotation, and approve increases in remuneration for Managing Director Ashish Narayan Sakalkar, Whole Time Director and CEO Saili Jayaram More, and Non-Executive Director Sachin Chandrakant Badakh.

Asston Pharmaceuticals Limited, formerly Asston Pharmaceuticals Private Limited, held its 2nd Extraordinary General Meeting on July 31, 2026, via video conferencing, where shareholders approved a resolution to issue equity shares on a preferential basis. The company secretary informed shareholders that the electronic voting window will remain open for 15 minutes post the conclusion of the EGM, and the voting results, along with the scrutinizer's report, will be announced within two working days and placed on the company's website and the BSE Limited.

Asston Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 31 July 2026.

Asston Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 July 2026.